Press Release Details
Twist Bioscience Showcases New Innovation Lab at SynBioBeta 2019
-- Previews Disruptive Gene Pools Product that Includes up to 180,000 Genes for Drug Discovery, Protein Screening and More, at
-- Silicon-based DNA Synthesis Platform Continues to Enable Innovative Products Across Synthetic Biology, Next-Generation Sequencing,
“Building on the advancement and maturation of the synthetic biology community, we continue to apply our proprietary DNA synthesis platform to new initiatives that efficiently eliminate bottlenecks in workflow, as well as allow researchers to further disrupt static processes and approach previously unsolvable problems through a new avenue,” said Emily M. Leproust, Ph.D., CEO and co-founder of
“With an infrastructure in place to explore bleeding-edge research challenges, we are committed to driving the responsible research needed to identify new diagnostic tools and therapies for devastating diseases, to continue to uncover the mysteries of biology and enable more sustainable agricultural and chemical products worldwide,” commented
Gene Pools: Writing the Future of Synthetic Biology
The growth of the synthetic biology industry continues to see incredible innovation and new applications facilitated by unlimited access to the building blocks of research, including synthetic DNA at unprecedented scale. Where previously researchers worked in individual workflows with one gene in one tube, the explosion of biological information provides new opportunities to work in massively parallel workflows to exponentially accelerate the rate and scope of research. Designed with the flexibility to have up to 180,000 genes in a single tube at an affordable price,
Robust Product Portfolio for Synthetic Biology Success
Twist’s proprietary DNA synthesis platform currently enables two robust product lines:
-
Synthetic biology: A product line delivering high-quality synthetic DNA in different formats for a wide range of research needs in healthcare, industrial chemicals, agricultural biotechnology and academia
- Clonal Genes up to five kilobases, scalable synthesis, no order limitation
- Gene Fragments designed to be inserted into workflow, 1:3000 error rate
- Oligonucleotide Pools, up to 1 million oligos, 300 bases, industry-leading pricing, error rate 1:2000
-
Variant Libraries , site saturation and combinatorial libraries
- Next-generation sequencing: A product line built on Twist’s ability to synthesize DNA at scale to create custom double-stranded DNA probes for uniform target enrichment
- Human Core Exome Kit – Uniform enrichment of target regions, unparalleled specificity even at high sequencing depths, reduced overall sequencing cost
- Custom Panels – Rapid and scalable implementation of custom exomes, proprietary design algorithm for balanced capture
- Fixed Panels –
Human RefSeq Panel ,Pan-Viral Panel ,Mouse Exome Panel - Library Prep Kit – Supports automated workflows, wide range of DNA input types
- Fast Hyb & Wash Kit – 15-minute Fast Hyb supports sample to sequencer in one day
In addition, Twist is applying its technology to two vertical market opportunities. The first is Twist Biopharma, a division of
Its second vertical market opportunity embraces the ability to store digital data in DNA, with the benefits of permanence, universal format, density, and energy savings. Twist has demonstrated proof-of-concept projects to preserve cultural and historical information for potentially thousands of years.
Twist Bioscience Engagement at SynBioBeta 2019
-
Tuesday, October 1, 2019 ,2:30pm ,Bill Peck , Ph.D., Chief Technology Officer and Co-Founder ofTwist Bioscience on DNA data storage -
Tuesday, October 1, 2019 ,5:30pm ,Aaron Sato , Ph.D., Chief Scientific Officer, Twist Biopharma, a division ofTwist Bioscience on biopharma antibody discovery -
Wednesday, October 2, 2019 ,1:30pm , Emily Leproust, Ph.D., CEO and Co-Founder ofTwist Bioscience on the company -
Thursday, October 3, 2019 ,12:30pm ,Rebecca Nugent , Ph.D., Director of Research and Development,Twist Bioscience on redesigning the research funnel - Booth #225 in the Exhibit Hall
About
Follow us on Twitter |
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005471/en/
Source:
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com